Product Images Duloxetine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Duloxetine NDC 70518-2756 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Duloxetine 20mg 70518 2756 00
Duloxetine Delayed-release 20mg capsule is a medication manufactured by Prasco Laboratories that comes in a pack of 30. Its NDC number is 70518-2756-00 and the source NDC is 66993-0662-60. The directions for use should be found in the package insert. The expiry date and lot number are not available. It is recommended to keep the medication out of children's reach.*
Figure-1 - duloxetine fig1
This appears to be a graph that shows the proportion of patients with relapse over time from randomization to relapse, for two different treatments: placebo and duloxetine. The graph is displayed on a scale of 0 to 1 on the y-axis and time (in days) on the x-axis. The data seems to suggest that the proportion of patients with relapse is lower in the duloxetine treatment group compared to the placebo group over time.*
Duloxetine Figure 2 - duloxetine fig2
The text is a figure caption of a Kaplan-Meier estimation graph that shows the proportion of patients with relapse in a study (GAD Study 4) comparing a placebo treatment with a treatment of duloxetine. The x-axis shows the time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph suggests that the treatment with duloxetine reduces the risk of relapse compared to placebo.*
Figure 3: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1 - duloxetine fig3
The text is describing a figure showing the percentage of patients achieving various levels of pain relief from baseline as measured by 24-hour average pain severity. The figure compares treatment with Duloxetine 60mg BID, Duloxetine 60mg QD and Duloxetine 20mg QD against a placebo.*
Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4
The text presents a graph named "Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2" with three lines indicating the percentage of patients who improved taking Duloxetine 60 mgBID, Duloxetine 60 mg QD, and Placebo.*
Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5
Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6
This seems to be a graph showing the percentage of patients achieving various levels of pain relief when treated with a combination of Placebo and Duloxetine. The x-axis seems to indicate the percentage improvement in pain, whereas the y-axis seems to represent the percentage of patients achieving that level of pain relief. The graph seems to be specifically related to Chronic Low Back Pain (CLBP-3) treatment.*
Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7
Structure - duloxetine str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.